Plus Therapeutics Company Insiders
| PSTV Stock | USD 0.43 0.05 13.16% |
Plus Therapeutics' insiders are aggressively buying. The analysis of the overall insider sentiment regarding Plus Therapeutics suggests that vertually all insiders are extremely bullish. Plus Therapeutics employs about 21 people. The company is managed by 11 executives with a total tenure of roughly 49 years, averaging almost 4.0 years of service per executive, having 1.91 employees per reported executive.
Insider Sentiment 100
Aggressively Buying
Selling | Buying |
Latest Trades
| 2024-09-13 | Richard J Hawkins | Acquired 4000 @ 1.5 | View | ||
| 2024-09-11 | Howard Clowes | Acquired 5000 @ 1.34 | View | ||
| 2024-09-10 | Marc H Hedrick | Acquired 8000 @ 1.23 | View |
Monitoring Plus Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Plus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. Plus Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (1.0559) % which means that it has lost $1.0559 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.225) %, meaning that it created substantial loss on money invested by shareholders. Plus Therapeutics' management efficiency ratios could be used to measure how well Plus Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Plus Therapeutics' Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to climb to 1.52 in 2025, despite the fact that Return On Tangible Assets are likely to grow to (2.13). Intangibles To Total Assets is likely to climb to 0.19 in 2025, whereas Total Assets are likely to drop slightly above 6.3 M in 2025.Common Stock Shares Outstanding is likely to climb to about 9.7 M in 2025, whereas Net Loss is likely to drop (24.5 M) in 2025.
Plus Therapeutics Workforce Comparison
Plus Therapeutics is regarded second in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 96.0. Plus Therapeutics totals roughly 21.0 in number of employees claiming about 22% of equities under Health Care industry.
Plus Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Plus Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Plus Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Plus Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Plus Therapeutics Notable Stakeholders
A Plus Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Plus Therapeutics often face trade-offs trying to please all of them. Plus Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Plus Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| MD MBA | CEO President | Profile | |
| Russell Bradley | President Diagnostics | Profile | |
| Andrew CPA | VP CFO | Profile | |
| John Fraser | Chief Scientist | Profile | |
| Gary CPA | Advisor | Profile | |
| MS MBA | New Strategy | Profile | |
| Marc MD | CEO Pres | Profile | |
| Desiree Smith | Principal Controller | Profile | |
| Andrew Sims | VP CFO | Profile | |
| FACNP FACP | Chief VP | Profile | |
| Michael Rosol | Chief Officer | Profile |
About Plus Therapeutics Management Performance
The success or failure of an entity such as Plus Therapeutics often depends on how effective the management is. Plus Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Plus management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Plus management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.24) | (2.13) | |
| Return On Capital Employed | 1.65 | 1.73 | |
| Return On Assets | (1.96) | (1.86) | |
| Return On Equity | 1.45 | 1.52 |
Please note, the imprecision that can be found in Plus Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Plus Therapeutics. Check Plus Therapeutics' Beneish M Score to see the likelihood of Plus Therapeutics' management manipulating its earnings.
Plus Therapeutics Workforce Analysis
Traditionally, organizations such as Plus Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Plus Therapeutics within its industry.Plus Therapeutics Manpower Efficiency
Return on Plus Therapeutics Manpower
| Revenue Per Employee | 277.3K | |
| Revenue Per Executive | 529.5K | |
| Net Loss Per Employee | 618K | |
| Net Loss Per Executive | 1.2M |
Additional Tools for Plus Stock Analysis
When running Plus Therapeutics' price analysis, check to measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.